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hospitals from China, Hong Kong, India, Singapore, Taiwan and Thailand. The incidence and species distribution of candidaemia were
determined. There were 1601 episodes of candidaemia among 1.2 million discharges. The overall incidence was 1.22 episodes per 1000
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p://dx.doi.org/10.1016/j.cmi.2015.06.010IntroductionCandida species cause a spectrum of infections, ranging from
superﬁcial candidiasis of the skin and mucosal surfaces to life-
threatening bloodstream infection. The incidence ofEuropean Society of Clinical Microbiology and Infectious Diseases
nses/by-nc-nd/4.0/)
CMI Tan et al. Epidemiology of candidaemia in Asia 947candidaemia has increased over the last ﬁve decades, reﬂecting
advances in medicine as well as the growing population of
immunocompromised hosts [1–3]. Candida species, as a whole,
were one of the top four causes of healthcare-associated
bloodstream infections [1,2].
The epidemiology of candidaemia varies between regions and
over time [1–3]. Although there are many publications from
Asian countries, a large-scale cross-sectional study of candidi-
asis across Asia has not been performed. We conducted a
laboratory-based systematic surveillance study to determine
the incidence and distribution of candidaemia in 25 hospitals
located in six Asian countries/regions. Data on candidaemia
from other continents were used for comparison.MethodsStudy design and participants
This laboratory-based surveillance study, designed by the Asia
Fungal Working Group (AFWG) under the International So-
ciety for Human and Animal Mycology, was conducted at 25
hospitals in China (n = 10), Hong Kong (n = 1), India (n = 4),
Singapore (n = 1), Taiwan (n = 6) and Thailand (n = 3). The
study was approved by the Institutional Review Board or
Research Ethics Committee at 21 hospitals. The approval of the
research at four centres was waived.
Mycology data collection
We obtained data of fungi isolated from clinical specimens from
1 July 2010 through 30 June 2011 from the microbiology or
mycology laboratories of each study site. For each isolate, the
following data were collected: de-identiﬁed patient code,
specimen collection date, specimen source/type, hospital ser-
vices, genus and species name if available. Data on all consec-
utive Candida blood isolates were analysed.
Hospital background information
We collected the following information from each study site:
country, city, geographic location, type of hospital (primary
care, referral centre or both); total number of beds, number of
haemato-oncology beds and intensive care unit (ICU) beds. The
total number of admission/discharges and patient-days, and the
number of outpatients during the study period were also noted.
We surveyed mycology laboratory practice on a basis of a
structured questionnaire.
Data analysis
The incidence of candidaemia (episodes/1000 discharges), inci-
dence density (episodes/1000 patient-days) and the species
distribution of non-duplicate blood Candida isolates wereClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an open access artidetermined for each hospital, each country and overall. Overall
incidences were expressed as pooled mean rates calculated by
aggregating numerators and dividing by the sum of de-
nominators from all sites. Candida isolates were considered
duplicate if the same Candida species came from the same type
of specimen collecting within 7 days. Candida isolates from
blood cultures separated by >7 days were considered distinct
episodes.
Categorical variables were analysed using chi-square test or
Fisher exact test, and continuous variables were compared
using the Student’s t test or Wilcoxon test, as appropriate.
Pearson’s correlation and regression (simple linear regression)
were used to investigate the relationship between two
continuous variables. The correlation coefﬁcient, a p value and
a conﬁdence interval were calculated. All analyses were per-
formed using SAS software (version 9.3; SAS Institute, Cary,
NC, USA).ResultsStudy sites and Candida isolates
During the study period, there were 1.2 million discharges and
264 million outpatients at the 25 participating hospitals.
Table S1 (see Supplementary material) shows the background
information of these hospitals. The blood culture system and
methods of Candida identiﬁcation are summarized in Table S2
(see Supplementary material). Data from 51 254 fungal iso-
lates were analysed (see Supplementary material, Table S3). Of
37 337 Candida clinical isolates, 3196 (8.5%) were blood iso-
lates. Of 27 448 non-duplicate Candida isolates with known
species identity, 98.4% were among the top ﬁve species iden-
tiﬁed (Candida albicans, Candida tropicalis, Candida glabrata,
Candida parapsilosis and Candida krusei). Table S4 (see Supple-
mentary material) shows the distribution of Candida species by
specimen type.
Incidence of candidaemia and its relationship to
hospital characteristics
From 1601 episodes of candidaemia, 1910 non-duplicate
Candida blood isolates were identiﬁed to the species level,
giving an overall incidence of 1.22 episodes/1000 discharges or
0.15 episodes/1000 patient-days. The incidence rate varied
greatly among the participating hospitals; the study site with the
highest incidence was in India (4.53 episodes/1000 discharges),
whereas Taiwan had the highest incidence by country/region
(2.93 episodes/1000 discharges) (Table 1).
The distribution of candidaemia by hospital service is shown
in Fig. 1. More than half of the patients who developed candi-
daemia were in medical or surgical wards. We analysed theof European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 946–953
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
TABLE 1. Incidence of candidaemia by country/region1
Country or region Setting or population Study period
No. of
episodes Incidence (range) Incidence density (range) Reference
Hospital-based survey
China 9 hospitals 2010–2011 310 0.38 per 1000 discharges
(0.16–0.74)
0.05 per 1000 patient-days
(0.01–0.06)
Current study
Hong Kong 1 hospitals 2010–2011 30 0.25 per 1000 discharges 0.07 per 1000 patient-days Current study
India 3 hospitals 2010–2011 333 1.94 per 1000 discharges
(0.30–4.53)
1.24 per 1000 patient-days
(0.30–1.77)
Current study
Singapore 1 hospitals 2010–2011 73 NA 0.15 per 1000 patient-days Current study
Taiwan 6 hospitals 2010–2011 1104 2.93 per 1000 discharges
(1.99–3.89)
0.37 per 1000 patient-days
(0.20–0.56)
Current study
Thailand 3 hospitals 2010–2011 130 1.31 per 1000 discharges 0.17 per 1000 patient-days Current study
Asia 25 hospitals in 6 countries/ regions 2010–2011 1601 1.22 per 1000 discharges
(0.16–4.53)
0.15 per 1000 patient-days
(0.01–1.77)
Current study
Latin American 21 tertiary care hospitals in
7 countries
2008–2010 672 1.18 per 1000 admissions
(0.21–2.98)
0.23 per 1000 patient-days
(0.06–0.39)
[4]
Italy 34 hospitals 2009 467 1.19 per 1000 admissions [5]
UK A tertiary referral center. 2005–2008 107 0.109 per 1000 bed-days [6]
Intensive care units (ICUs)
Asia ICUs in 25 hospitals in 6
countries/regions
2010–2011 370 11.7 per 1000 discharges Current study
India 27 ICUs 2011–2012 1,400 6.51 per 1000 ICU admission [7]
China 67 adult ICUs 2009–2011 306 3.2 per 1000 ICU admission [8]
Italy 18 adult ICUs 2007–2008 92 16.5 cases per 1000 admissions [9]
Germany 682 ICUs 2006–2011 523 0.24 per 1000 patients 0.07 per 1000 patient-days [10]
Population-based survey
Spain Population survey (29 hospitals
in ﬁve municipal areas)
2010–2011 773 8.1 cases per 100 000 inhabitants
0.89 per 1000 admissions
1.36 per 10 000 patient-days [11]
USA Population survey 2008–2011 2675 13.3 per 100 000 person-years in Atlanta;
26.2 per 100 000 person-years in
Baltimore
[12]
Australia Nationwide survey 2000–2004 1095 1.81 per 100 000 population and 0.21
per 1000 separations
[13]
Iceland Nationwide survey 2000–2011 208 5.7 per 100 000 population/year [14]
Finland Nationwide survey 2004–2007 603 2.86 per 100 000 population [15]
1Pubmed search using the following phrase: ((candidemia[Title/Abstract]) OR invasive candidiasis[Title/Abstract])) AND (“2010/1/1”[Date - Publication] : “2014/1/1”[Date -
Publication]) AND incidence[Text Word], accessed on 1 January 2014, limited to European and American countries, and excluded those limited to speciﬁc patient population or
speciﬁc Candida species. When more than one publication was found, the publication most representative of the country/region was selected.
948 Clinical Microbiology and Infection, Volume 21 Number 10, October 2015 CMIassociation between candidaemia incidence and hospital infor-
mation such as the number of beds, patients and patient-days in
the ICU or haemato-oncology wards. We found that the ICU/
total bed ratio affected the incidences of candidaemia signiﬁ-
cantly (R2 = 0.4734, p 0.001, simple linear regression), but the
haemato-oncology/total bed ratio did not (R2 = 0.0442, p 0.40).Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceWe further analysed the relationship between candidaemia
and mycology laboratory workload. The total number of fungal
isolates and the number of Candida blood isolates were highly
correlated among the six countries (R2 = 0.8699, p 0.02,
Pearson’s correlation) and among the 25 hospitals (R2 = 0.7698,
p < 0.0001). On the other hand, the incidence of candidaemiaFIG. 1. Distribution of patients with candi-
daemia by hospital service (number denotes
%).
European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 946–953
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fungal isolates/1000 discharges) at both country and hospital
levels (R2 = 0.37464, p 0.11). Among six hospitals in Taiwan,
however, the incidence of candidaemia was highly correlated
with the workload of the mycology laboratory (R2 = 0.8714, p
0.05).
Species distribution of candidaemia
Of 1910 non-duplicate blood Candida isolates identiﬁed to the
species level, C. albicans was the most frequently isolated spe-
cies (41.3%), followed by C. tropicalis (25.4%), C. glabrata
(13.9%) and C. parapsilosis (12.1%). These four Candida species
accounted for 92.9% of candidaemia cases (Fig. 2). Although
C. albicans was the most common Candida species, it accounted
for <40% of candidaemia in 12 of 25 hospitals in our study
(median 41.9%, range 5.56–58.3%).
Among non-albicans blood isolates, the spectrum and inci-
dence of Candida species varied among hospitals (Fig. 3).
Candida tropicalis was the leading non-albicans species overall,
accounting for 9.1–83.3% (median 23.0%) of blood isolates.
Candida tropicalis was the most common non-albicans Candida
species in 18 hospitals: China (6/10), Hong Kong, India (3/4),
Singapore, Taiwan (4/6) and Thailand (3/3).
The relative distributions of the four common Candida spe-
cies varied among the countries. The proportion of C. tropicalis
among blood isolates was higher in tropical areas (India,
Thailand and Singapore) than other geographical regions (46.2%
versus 18.9%, p 0.04).
Candida glabrata was the most common non-albicans Candida
species in 3 of 25 hospitals (two in China; one in Taiwan). Up to
26% of candidaemia was caused by C. glabrata in two hospitals
(one in China; one in Singapore). Candida parapsilosis was the
most common non-albicans Candida species in 3 of 25 hospitals,
accounting for 33% of candidaemia cases in one Indian hospital,FIG. 2. Species distribution of 1910 non-
duplicate Candida blood isolates identiﬁed to
the species level (number denotes %).
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an open access arti26% in a Chinese hospital and 14% in a Taiwanese hospital.
Candida krusei was rare, but contributed to 12.2% of Candida
blood isolates in one Indian hospital.
Distribution of hospital services
Of the 1601 episodes of candidaemia, 23.1% occurred in the
ICUs and 10.1% in haemato-oncology wards (Fig. 1). The
overall incidence of candidaemia in ICUs was 11.7 episodes/
1000 patients. Species distribution of Candida was similar in ICU
patients and non-ICU patients (data not shown). Conversely,
C. tropicalis was more frequently isolated in haemato-oncology
wards than in other wards (33.7% versus 24.5%, p 0.0058).
There were 109 episodes (5.57%) reported from emergency
departments. The leading four species were C. albicans (36
episodes), C. glabrata (25 episodes), C. tropicalis (24 episodes)
and C. parapsilosis (13 episodes). Of 15 episodes reported at
outpatient clinics, ﬁve were due to C. parapsilosis, followed by
C. albicans (four episodes) and C. tropicalis (three episodes).
Rare fungi
Among 1910 non-duplicate Candida blood isolates, the
following 11 Candida species contributed 6.1%: Candida guil-
liermondii (n = 43), Candida krusei (n = 37), Candida famata
(n = 17), Candida pelliculosa (n = 14), Candida haemulonii (n = 7),
Candida intermedia (n = 5), Candida lusitaniae (n = 5), Candida
sake (n = 4), C. dubliniensis (n = 2), Candida pararugosa (n = 1)
and Candida catenulate (n = 1) (Fig. 2). Twenty-two of 43
C. guilliermondii isolates were isolated from different units at a
single hospital in India (ﬁve medical wards; three surgical wards;
six paediatric wards; ﬁve ICUs; three emergency departments)
and accounted for 11.7% of Candida blood isolates. Twenty-
three of 37 C. krusei isolates were reported from the same
hospital and accounted for 12.2% of Candida blood isolates. Ten
of 17 C. famata isolates were identiﬁed at another Indianof European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 946–953
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
FIG. 3. Geographic locations of the 25 participating study sites. The size of the circles indicates the relative number of candidaemia episodes in each
site. Only Candida species of 20 or more episodes at each study site are shown. The inset represents Taiwan.
950 Clinical Microbiology and Infection, Volume 21 Number 10, October 2015 CMIhospital and distributed in different wards (four medical wards;
ﬁve surgical wards; one paediatric ward). Ten out of 14 epi-
sodes of C. pelliculosa were reported from a single hospital in
Taiwan, eight of which occurred in the ICU.
Previous Candida colonization/infection
Of 1910 non-duplicate Candida blood isolates evaluated, the
same Candida species from non-blood specimens were identi-
ﬁed in 181 patients (9.48%) in the preceding 7 days and in 302
patients (15.8%) in the preceding 30 days. Candida albicans
ranked the top among colonizing/infecting species (23.4%),
followed by C. glabrata (13.5%), C. tropicalis (10.7%),
C. parapsilosis (9.3%) and C. guilliermondii (9.5%), C. pelliculosa
(7.1%) and C. krusei (5.4%). Of 302 previous colonizations/in-
fections, 118 were isolated from the urinary tract.DiscussionA few studies pertaining to different aspects of candidaemia in
Asian countries have been published (details other than those in
Table 1 are provided in the Supplementary material, text), but
none has attempted a multi-country overview and comparisonClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licein Asia such as ours. This study showed great variability in the
incidence and species distribution of Candida isolates among the
hospitals, though the reason is not clear. The ﬁnding that ICU/
total bed ratios signiﬁcantly affected the incidences of candi-
daemia explains partly the reason of variation of candidaemia.
Yet, our study showed a possible shift of candidaemia from the
ICU cases to the general hospital population, as the ICUs
accounted for only 23% of episodes. Further, the association of
candidaemia incidences and the total number of haemato-
oncology/total bed ratios was not signiﬁcant. However, not all
haemato-oncology patients were admitted to dedicated
haemato-oncology beds in several study sites. In addition, anti-
fungal prophylaxis policies in individual haemato-oncology units
and ICUs are difﬁcult to quantify in the 25 hospitals through a
laboratory surveillance study. The method and frequency of
blood culture sampling is also likely to vary across the 25
hospitals. The migration of people from rural areas into cities, a
problem in many parts of Asia, probably leads to pressure in
hospital beds in Asian cities.
At the country level, the highest incidence of candidaemia
was 2.93 episodes/1000 patients in Taiwan. The number of
persons at risk of candidaemia may have increased in this
country, as shown in a recent hospital-based population studyEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 946–953
nses/by-nc-nd/4.0/)
CMI Tan et al. Epidemiology of candidaemia in Asia 951[16]. The ever-advancing economy with increased access to
healthcare, including more advanced care such as chemo-
therapy and transplantation, are important considerations
throughout Asia [12,16], and these factors may lead to a rise in
the incidence of candidaemia.
Data on candidaemia from other continents were identiﬁed
through literature review and summarized in Table 1 for
comparison [4–15]. A Latin-American survey reported a great
variability of candidaemia incidence across the different coun-
tries and centres [4]. In terms of incidence-density, the rates
(per 1000 patient-days) of candidaemia in these two continents
(Latin America and Asia) are similar, with the notable exception
of India, which had a high rate (>1 per 1000 patient-days).
The distribution of common Candida species across Asia is
an important ﬁnding of this study. In the USA and UK,
C. glabrata is the most frequently isolated non-albicans Candida
species [1,3,6,12,17]. In this study’s cohort, Candida glabrata
was not generally common, but accounted for 26% of candi-
daemia in one hospital each in China and Singapore, which is
similar to levels in the USA [3,13,18]. Compared with other
continents [4–6,12,13], the proportion of C. tropicalis was
relatively high in this cohort (25%) and Latin American (18%)
[4], and low in Europe (8%) [5,6] and Australia (5%) [13].
Candida tropicalis candidaemia appears to be more common in
tropical countries (e.g. India, Singapore and Thailand) (see
Supplementary material, Fig. S1a). Data from Japan [18] and
South Korea [19,20] appear to support this trend, with
C. tropicalis accounting for somewhat lower rates of candidae-
mia. Country data from Latin America plotted by geographic
location showed a similar geographic trend, with C. tropicalis
being more common in the tropical region of South America
(see Supplementary material, Fig. S1b). Candida tropicalis was
ﬁrst identiﬁed as Endomyces tropicalis in bronchomycosis in Sri
Lanka [21]. It would be interesting to speculate that its tropical
origin may be associated with its pathogenicity in warmer
climates.
Candida tropicalis was more likely to be isolated in haemato-
oncology wards. Studies have shown the association between
chemotherapy-induced neutropenia and infection with
C. tropicalis [1,22]. Candidaemia in patients with haematological
malignancies are most probably endogenous in origin, i.e. due to
translocation from the gut [23]. Hence, our ﬁndings suggest that
both geographic factors and healthcare practices contribute to
the variation of species distribution.
These ﬁndings raise concern, because there are unique fea-
tures of C. tropicalis infections compared with other Candida
species. The time-to-positivity of blood cultures of C. tropicalis
was signiﬁcantly shorter than that of other species [24]. Clini-
cally, septic shock and skin emboli are common ﬁndings of
C. tropicalis candidaemia [25]. Both short time-to-positivity andClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an open access artiseptic shock are associated with poor prognosis [26]. In addi-
tion, a recent survey in Taiwan identiﬁed genetically related
C. tropicalis isolates from human and environmental samples
exhibiting reduced susceptibility to ﬂuconazole [27]. Hence,
proactive monitoring of ﬂuconazole susceptibility is required in
regions where C. tropicalis predominates and where ﬂuconazole
is used upfront without in vitro susceptibility testing.
Among rare Candida species, C. pelliculosa, also known as
Pichia anomala or Hansenula anomala, is mainly found in plants,
fruits and oil. Ten out of 14 episodes in this cohort were re-
ported from a single hospital, clustered in the ICUs. In the
preceding year, this hospital identiﬁed a monoclonal outbreak
of C. pelliculosa [28]. Similarly, the fact that there was a clus-
tering of cases of C. guilliermondii candidaemia from one Indian
hospital is worrying. At least one other centre has described
such clustering of C. guilliermondii infections [29]. This ﬁnding,
again, shows the importance of epidemiology studies because
many hospitals in Asia do not routinely perform species iden-
tiﬁcation, and so may underestimate potential fungal outbreaks.
Although this study covered 25 hospitals located at various
geographic regions in Asia, it has several limitations. First, all
participating hospitals except one are referral centres and,
hence, might not be representative of the hospitals in this re-
gion. Second, only laboratory data were collected. Third, not all
Candida isolates were identiﬁed to the species level. In this
study, 2.5% of blood isolates were not identiﬁed to the species
level. Fourth, all isolates were identiﬁed in the local laboratory
without being sent to a central reference laboratory for
conﬁrmation. Misidentiﬁcation by the laboratories cannot be
excluded. Furthermore, this study did not provide antifungal
susceptibility data.
In conclusion, this study provides a general picture of the
incidence and distribution of candidaemia in Asia for global
comparison as well as for individual hospitals to benchmark
their data against national and international peers. There is
great variability both in the incidence and species distribution of
Candida isolates among the study hospitals and we provide
possible reasons, including ICU/total bed ratio, for incidence
and geographic localization for species distribution. Aggressive
diagnoses including the detection of Candida blood isolates and
identiﬁcation to the species level are important for both patient
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